PHVS — Pharvaris N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1830487 ·
Netherlands
Last close
$32.62
Market Cap
$2.28B
52W High
$36.60
52W Low
$28.33
ADV30
488,027
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -44,272,001 | -39,200,673 | 259,788,041 | 246,957,998 | 23,455,647 |
| Dec 2025 | 0 | — | -47,599,025 | -46,740,853 | 301,454,999 | 291,678,888 | 30,180,665 |
| Sep 2025 | 0 | — | -39,664,499 | -37,137,035 | 338,896,201 | 329,285,629 | 26,655,561 |
| Jun 2025 | 0 | — | -40,373,097 | -45,480,686 | 209,810,326 | 199,571,685 | 25,474,434 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-137,073,634
Investing CF
$-164,619
Financing CF
$160,607,219
CapEx
$-342,172
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-579,596,307
Inventory
—
Receivables
$4,551,123
ST Investments
—
EBIT TTM
$-169,822,932
Pretax Income TTM
$-173,711,496
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,822,932 | -175,699,397 | 301,454,999 | 30,180,665 | — | -137,073,634 |
| Dec 2024 | 0 | -145,688,167 | -134,221,527 | 291,374,765 | 23,614,024 | — | -120,130,191 |
| Dec 2023 | 0 | -96,913,620 | -100,875,068 | 398,694,465 | 14,646,062 | — | -93,049,093 |
| Dec 2022 | 0 | -86,714,608 | -76,332,557 | 167,732,983 | 18,473,953 | — | -67,162,634 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.26B | $20.31 | — |
| VERA | Vera Therapeutics, Inc. | $2.30B | $32.10 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.25B | $25.52 | — |
| PGEN | PRECIGEN, INC. | $2.24B | $6.27 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
2026-07-31 13:55 · Yahoo
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
2026-07-24 11:21 · Yahoo
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
2026-07-22 10:50 · Yahoo
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
2026-07-15 16:00 · Yahoo
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
2026-07-15 13:33 · Yahoo
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
2026-07-14 13:55 · Yahoo
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development
2026-07-06 20:33 · Yahoo
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
2026-07-06 10:50 · Yahoo
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
2026-06-15 10:50 · Yahoo
Pharvaris Announces Annual General Meeting of Shareholders
2026-06-11 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.